Tarsus Pharmaceuticals, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $32.3M | $181.5M | $175.0M |
| Jun 2022 | $31.3M | $252.8M | $245.4M |
| Sep 2022 | $33.8M | $236.5M | $169.5M |
| Dec 2022 | $35.0M | $227.9M | $71.7M |
| Mar 2023 | $37.8M | $211.2M | $66.0M |
| Jun 2023 | $41.2M | $188.9M | $106.8M |
| Sep 2023 | $54.7M | $268.3M | $226.7M |
| Dec 2023 | $68.5M | $265.5M | $224.9M |
| Mar 2024 | $74.1M | $349.3M | $193.7M |
| Jun 2024 | $124.6M | $376.8M | $181.1M |
| Sep 2024 | $138.8M | $376.3M | $176.2M |
| Dec 2024 | $152.5M | $377.0M | $94.8M |
| Mar 2025 | $158.3M | $500.8M | $175.8M |
| Jun 2025 | $162.4M | $495.0M | $96.6M |
| Sep 2025 | $199.5M | $534.6M | $112.7M |
| Dec 2025 | $218.7M | $562.2M | $183.6M |
| Mar 2026 | $232.2M | $581.1M | $102.2M |
| Jun 2026 | $264.4M | $611.1M | $204.6M |